Get startedLog in
    Picture of Lakefront Biotherapeutics NV logo

    LKFT — Lakefront Biotherapeutics NV News Story

    0.000.00%
    nl flag iconLast trade - 00:00
    HealthcareBalancedMid CapNeutral
    All News

    Brief: Galapagos: FDA Clears IND Application For Phase 1/2 ATALANTA-1 Study

    Picture of Lakefront Biotherapeutics NV logoLakefront Biotherapeutics NV
    23/08/2024 06:04
    Aug 23 (Reuters) - Galapagos NV  GLPG.AS :
    * GALAPAGOS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR
PHASE
1/2 ATALANTA-1 STUDY OF CD19 CAR-T, GLPG5101, IN
RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA

Source text for Eikon:  ID:nGNX1gGlDF 
Further company coverage:  GLPG.AS 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on Lakefront Biotherapeutics NV

    See all news